Overview

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics of vildagliptin (LAF237) and its metabolites in patients with mild renal impairment compared to their sex, age and weigh based healthy volunteer counterparts.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin